Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.84
OPK's Cash to Debt is ranked lower than
70% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. OPK: 2.84 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 2.84

Equity to Asset 0.54
OPK's Equity to Asset is ranked lower than
64% of the 599 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPK: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s 10-Year Equity to Asset Range
Min: -0.41   Max: 0.96
Current: 0.54

-0.41
0.96
F-Score: 5
Z-Score: 6.07
M-Score: -3.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -174.31
OPK's Operating margin (%) is ranked lower than
59% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. OPK: -174.31 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44   Max: -39.08
Current: -174.31

-31624.44
-39.08
Net-margin (%) -246.86
OPK's Net-margin (%) is ranked lower than
64% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. OPK: -246.86 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54   Max: -4.59
Current: -246.86

-44561.54
-4.59
ROE (%) -28.35
OPK's ROE (%) is ranked lower than
51% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. OPK: -28.35 )
Ranked among companies with meaningful ROE (%) only.
OPK' s 10-Year ROE (%) Range
Min: -3194.35   Max: -1.4
Current: -28.35

-3194.35
-1.4
ROA (%) -18.07
OPK's ROA (%) is ranked higher than
55% of the 835 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. OPK: -18.07 )
Ranked among companies with meaningful ROA (%) only.
OPK' s 10-Year ROA (%) Range
Min: -1352.71   Max: -0.83
Current: -18.07

-1352.71
-0.83
ROC (Joel Greenblatt) (%) -1041.44
OPK's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -353.07 vs. OPK: -1041.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130662.93   Max: -57.21
Current: -1041.44

-130662.93
-57.21
Revenue Growth (3Y)(%) 30.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
84% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. OPK: 30.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 135.1
Current: 30.1

0
135.1
EBITDA Growth (3Y)(%) 69.40
OPK's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. OPK: 69.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.7   Max: 171.4
Current: 69.4

-75.7
171.4
EPS Growth (3Y)(%) 139.10
OPK's EPS Growth (3Y)(%) is ranked higher than
99% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. OPK: 139.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.4   Max: 152.4
Current: 139.1

-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

OPK Guru Trades in Q2 2014

Paul Tudor Jones 13,145 sh (+7.28%)
Murray Stahl 125,930 sh (+2.24%)
Mario Gabelli 15,000 sh (unchged)
George Soros 235,600 sh (-84.24%)
» More
Q3 2014

OPK Guru Trades in Q3 2014

Murray Stahl 138,935 sh (+10.33%)
George Soros 235,600 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 11,000 sh (-26.67%)
» More
Q4 2014

OPK Guru Trades in Q4 2014

George Soros 235,600 sh (unchged)
Mario Gabelli 11,000 sh (unchged)
Murray Stahl 125,752 sh (-9.49%)
» More
Q1 2015

OPK Guru Trades in Q1 2015

Jim Simons 1,253,398 sh (New)
Paul Tudor Jones 38,137 sh (New)
Ken Fisher 29,200 sh (New)
Mario Gabelli 11,000 sh (unchged)
George Soros 235,600 sh (unchged)
Murray Stahl 94,824 sh (-24.59%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

OPKO CEO Is Building A Pharma Powerhouse And Continuously Buying Shares
OPKO Health (OPK) has come to my attention because I noticed that the chairman and CEO, Dr. Phillip Frost, has been consistently showing up on the list of CEO buys at GuruFocus. As I look back at the history, he has been doing so for years. According to the Form 4 filed with the SEC, his is the beneficial owner of shares in his own name, his trust, and an LLC. Together he is the beneficial owner of 158.71 million out of the 412.91 million shares outstanding, representing about 38 percent of the shares. As of 6/19/14, his position is valued at $1.457 billion. Phillip Frost has had many successful investments in the past, could this be the next one? Read more...

Ratios

vs
industry
vs
history
P/B 9.80
OPK's P/B is ranked lower than
80% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. OPK: 9.80 )
Ranked among companies with meaningful P/B only.
OPK' s 10-Year P/B Range
Min: 3.65   Max: 50.6
Current: 9.8

3.65
50.6
P/S 76.92
OPK's P/S is ranked lower than
84% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.45 vs. OPK: 76.92 )
Ranked among companies with meaningful P/S only.
OPK' s 10-Year P/S Range
Min: 15.25   Max: 126.5
Current: 76.92

15.25
126.5
PFCF 48.70
OPK's PFCF is ranked lower than
62% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. OPK: 48.70 )
Ranked among companies with meaningful PFCF only.
OPK' s 10-Year PFCF Range
Min: 38.97   Max: 49.5
Current: 48.7

38.97
49.5
POCF 48.05
OPK's POCF is ranked lower than
62% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 31.64 vs. OPK: 48.05 )
Ranked among companies with meaningful POCF only.
OPK' s 10-Year POCF Range
Min: 37.92   Max: 48.05
Current: 48.05

37.92
48.05
Current Ratio 2.16
OPK's Current Ratio is ranked lower than
72% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. OPK: 2.16 )
Ranked among companies with meaningful Current Ratio only.
OPK' s 10-Year Current Ratio Range
Min: 0.88   Max: 415
Current: 2.16

0.88
415
Quick Ratio 2.05
OPK's Quick Ratio is ranked lower than
69% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. OPK: 2.05 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s 10-Year Quick Ratio Range
Min: 0.48   Max: 415
Current: 2.05

0.48
415
Days Inventory 141.09
OPK's Days Inventory is ranked lower than
59% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. OPK: 141.09 )
Ranked among companies with meaningful Days Inventory only.
OPK' s 10-Year Days Inventory Range
Min: 131.84   Max: 500.07
Current: 141.09

131.84
500.07
Days Sales Outstanding 70.33
OPK's Days Sales Outstanding is ranked lower than
56% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. OPK: 70.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s 10-Year Days Sales Outstanding Range
Min: 38.86   Max: 727.85
Current: 70.33

38.86
727.85

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 11.90
OPK's Price/DCF (Projected) is ranked lower than
73% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OPK: 11.90 )
Ranked among companies with meaningful Price/DCF (Projected) only.
OPK' s 10-Year Price/DCF (Projected) Range
Min: 7.16   Max: 236.67
Current: 11.9

7.16
236.67
Price/Median PS Value 2.10
OPK's Price/Median PS Value is ranked lower than
64% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. OPK: 2.10 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s 10-Year Price/Median PS Value Range
Min: 0.31   Max: 9.67
Current: 2.1

0.31
9.67
Earnings Yield (Greenblatt) -2.30
OPK's Earnings Yield (Greenblatt) is ranked higher than
70% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.60 vs. OPK: -2.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
OPK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.9   Max: 0
Current: -2.3

-2.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Mexico, OPK.Israel,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Oppenheimer Weighs in on Biotech Stocks: Opko Health, OvaScience Inc May 13 2015 
Weekly CEO Buys Highlight: OPK, CLMS, GFF, TCB, SFNC May 12 2015 
CNN To Use Drone Aviation Holding's Products For FAA Research May 08 2015 
Weekly CEO Buys Highlight: APD, OPK, ASPS, ADTN, NSA May 05 2015 
Weekly CEO Buys Highlight: BH, GRIF, BXMT, OPK, RHP Apr 26 2015 
Weekly CEO Buys Highlight: NRZ, BH, OPK, DRI, CLMS Apr 17 2015 
Weekly CEO Buys Highlight: PHII, RHP, OPK, VNR, LUB Apr 02 2015 
Weekly CEO Buys Highlight: S, OPK, CAPL, CLF, MOSY Mar 09 2015 
Recent Stocks Impacted By Insider Buying Feb 21 2015 
Weekly CEO Buys Highlight: HES, GDOT, BH, CUBI, OPK Feb 09 2015 

More From Other Websites
2:43 pm Opko Health announces is has submitted an NDA to the US FDA for Rayaldee May 29 2015
OPKO Announces Submission of Rayaldee™ New Drug Application to U.S. Food and Drug Administration May 29 2015
OPKO Health to Present at the Jefferies 2015 Healthcare Conference May 27 2015
OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting May 18 2015
OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting May 18 2015
OPKO HEALTH, INC. Financials May 16 2015
OPKO Announces Publication of Study Using Kallikrein Biomarkers of the 4Kscore® Test in a Large... May 15 2015
MabVax Therapeutics Holdings, Inc. Provides Corporate Update and Reports First Quarter 2015... May 15 2015
Opko Health (OPK) Looks Good: Stock Adds 5.8% in Session - Tale of the Tape May 14 2015
3 Key Takeaways Following Opko's Earnings Results May 13 2015
10-Q for OPKO Health, Inc. May 13 2015
OPKO Health reports 1Q loss May 11 2015
OPKO Health reports 1Q loss May 11 2015
OPKO Announces First Quarter Operating and Financial Results May 11 2015
OPKO HEALTH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... May 11 2015
OPKO Announces First Quarter Operating and Financial Results May 11 2015
Ameliorating Prospects For Opko Health: What To Expect From Earnings And Beyond May 11 2015
Q1 2015 OPKO Health Inc Earnings Release - After Market Close May 11 2015
What Investors Can Expect from Pfizer in 2015 May 11 2015
Lightning Round: Nope. Still too early to buy this May 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK